Overview

• Published in Diabetes, Obesity and Metabolism, the retrospective study analyzed data from 679 overweight or obese patients treated with GLP-1RAs at Peking University People’s Hospital between November 2022 and October 2024.
• Semaglutide users had more than double the odds of significant weight loss compared with other GLP-1RA users at six months, with non-diabetic status boosting success rates (OR=2.18).
• Each additional month of GLP-1RA therapy was linked to incremental improvements in weight reduction over 12 months.
• Higher basal metabolic rate, greater skeletal muscle mass in limbs and abdomen, and elevated serum creatinine correlated with stronger weight-loss responses.
• Investigators say these real-world insights could support the development of individualized dosing and treatment strategies for obesity management.